SHINE Technologies | Production Facility Groundbreaking
SHINE’s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy’s toughest hurdles by recycling nuclear waste.
SHINE Technologies | NRC Accepts SHINE Application
SHINE’s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy’s toughest hurdles by recycling nuclear waste.
Insights & Updates | The Latest in Fusion Technology
Join us throughout this week as we dive deeper into the second phase of our business: Producing Medical Isotopes. We are combatting chronic shortages of nuclear medicine throughout the world. These shortages impact patient diagnoses and treatment of heart disease, cancer, and other serious illnesses.
Phase 2 | Producing Medical Isotopes Lu-177 and Mo-99
Producing Medical Isotopes. In Phase 2, we are combatting chronic shortages of critical nuclear medicine, domestically and across the globe. These shortages directly impact patient diagnoses and treatment of heart disease, cancer, and other serious illnesses.
SHINE Europe B.V. Designing Advanced Medical Isotopes Facility …
SHINE’s proprietary medical isotope production processes create non-carrier-added lutetium-177 and are expected to create molybdenum-99. In the future, SHINE plans to scale its fusion technology to help solve one of energy’s toughest hurdles by recycling nuclear waste.
Powering Patient Diagnostics with Molybdenum-99
Molybdenum-99 (or Mo-99), is the most-used diagnostic medical isotope in the world, powering 40 million patient scans each year. Nearly half of those scans, critical for detecting life-threatening conditionslike heart disease and cancer, are performed in North America.
About SHINE | A Safer, Healthier, Cleaner World Via Fusion
Veendam, the Netherlands is home to our European medical isotope production efforts. SHINE Europe will enhance our mission to bolster the nuclear medicine supply chain across the globe. Near-term, European efforts will focus on addressing urgent needs for …
SHINE Technologies | SHINE Technologies Collaborates with …
Simultaneously, SHINE is pioneering solutions in healthcare, producing essential medical isotopes like lutetium-177 and soon, molybdenum-99 for diagnostic and therapeutic use. Looking to the future, SHINE is leveraging its fusion knowledge to tackle complex energy challenges, including the potential for nuclear waste recycling and clean energy ...
SHINE Technologies | Illuminating the Path to Fusion Energy
Producing Medical Isotopes. for a healthier world >> Phase 3. Recycling Nuclear Waste. FOR A CLEANER WORLD >> Phase 4. Generating Fusion Energy. BELIEVE IN THE FUTURE >> Read Founder's Letter. Redefine What's Possible. We stand apart from other fusion companies because we have commercialized fusion today and we are scaling our technology ...
The Roles of Radiation and Neutron Generators in Medicine
SHINE’s medical isotope production capability comes in part from the advances we have made in compact, practical neutron generators. What makes SHINE’s technique for creating medical isotopes different from the norm?